Clinical Trial Search

Primary: Dose-escalation Safety lead-in: Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events (AEs) After Each Vaccination — 2; 3; 5; 5…

Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 17.3; 15.1; 17.3; 9.4 Percentage of participants

Primary: Mean Change in ODI From Baseline to 5 Years Post Intracept Procedure — 34.63 units on a scale

Primary: Gain in Visual Field With the Multiplexing Prism — 24 degrees

Primary: Rate of Participants With MACCE Events — 3 Participants

Primary: Adjusted Mean Percent Surface Microhardness Recovery (%SMHR) at 4 Hours (Test Dentifrice Versus (vs.) Placebo Control Dentifrice) — 32.20; 23.85 percent SMHR — p=0.0012

Primary: Functional Magnetic Resonance Imaging (fMRI) Task Data: BOLD Activation Changes Within Amygdala During Negative Faces in the Hariri Face Matching Task Between Placebo…

Primary: Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years…

Primary: Regional Total Volume of Distribution (VT) of [18F]-IMA601 in Frontal Lobe at Each Brain Scan — 14.09; 1.82; 4.76; 16.08 milliliters/cubic centimeter (mL/cm^3)

Primary: Number of Participants Who Completed EMA and EMA Plus Text Message Intervention or EMA Intervention Alone. — 39; 42 Participants

Primary: Change in Total NNAL: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol [ng/g Creatinine] — 0.97; 1.05 ng/g creatinine

Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants

Primary: Cigarette Use — -1.82 cigarettes

Primary: Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3…

Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants